BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection
BioMark Diagnostics (BMKDF) announced significant progress in its breast cancer detection program. The company's abstract on Lobular Breast Cancer (LBC) biomarker discovery has been accepted at the 2024 San Antonio Breast Cancer Symposium. The research demonstrates a simple, high-performing metabolite-based test for detecting LBC, which accounts for 10-15% of all breast cancers. This follows their October publication in the International Journal of Molecular Science highlighting a novel liquid biopsy assay for broader breast cancer detection. The company's platform combines metabolomics and machine learning for early cancer detection, focusing on developing accurate and accessible diagnostic tools.
BioMark Diagnostics (BMKDF) ha annunciato progressi significativi nel suo programma di rilevamento del cancro al seno. Il riassunto dell'azienda sulla scoperta dei biomarcatori per il Carcinoma Lobulare del Seno (LBC) è stato accettato al Simposio Internazionale sul Cancro al Seno di San Antonio 2024. La ricerca dimostra un test semplice e ad alte prestazioni basato su metaboliti per la rilevazione del LBC, che rappresenta il 10-15% di tutti i tumori al seno. Questo segue la loro pubblicazione di ottobre nella International Journal of Molecular Science che evidenziava un nuovo saggio di biopsia liquida per una più ampia rilevazione del cancro al seno. La piattaforma dell'azienda combina metabolomica e apprendimento automatico per la rilevazione precoce del cancro, concentrandosi sullo sviluppo di strumenti diagnostici accurati e accessibili.
BioMark Diagnostics (BMKDF) anunció un avance significativo en su programa de detección del cáncer de mama. El resumen de la compañía sobre el descubrimiento de biomarcadores para el Cáncer de Mama Lobulillar (LBC) ha sido aceptado en el Simposio Internacional sobre Cáncer de Mama de San Antonio 2024. La investigación demuestra una prueba simple y de alto rendimiento basada en metabolitos para detectar LBC, que representa el 10-15% de todos los cánceres de mama. Esto sigue a su publicación de octubre en la International Journal of Molecular Science, que destacaba un nuevo ensayo de biopsia líquida para la detección del cáncer de mama en general. La plataforma de la empresa combina metabolómica y aprendizaje automático para la detección temprana del cáncer, centrándose en desarrollar herramientas diagnósticas precisas y accesibles.
BioMark Diagnostics (BMKDF)는 유방암 검출 프로그램에서 중요한 진전을 발표했습니다. 소엽 유방암 (LBC) 바이오마커 발견에 대한 회사의 초록이 2024년 샌안토니오 유방암 심포지엄에서 수락되었습니다. 이번 연구는 LBC 검출을 위한 간단하고 성능이 뛰어난 대사물 기반 테스트를 보여주며, 이는 전체 유방암의 10-15%를 차지합니다. 이는 광범위한 유방암 검출을 위한 새로운 액체 생검 분석을 강조한 국제 분자 과학 저널의 10월 출판 뒤를 잇는 것입니다. 회사의 플랫폼은 조기 암 검출을 위한 대사체학 및 기계 학습을 결합하여 정확하고 접근 가능한 진단 도구를 개발하는 데 중점을 두고 있습니다.
BioMark Diagnostics (BMKDF) a annoncé des progrès significatifs dans son programme de détection du cancer du sein. Le résumé de la société sur la découverte de biomarqueurs pour le Cancer Lobulaire du Sein (LBC) a été accepté au Symposium International sur le Cancer du Sein de San Antonio 2024. La recherche démontre un test simple et performant basé sur des métabolites pour la détection du LBC, qui représente 10 à 15 % de tous les cancers du sein. Cela fait suite à leur publication d'octobre dans l'International Journal of Molecular Science mettant en avant un nouvel essai de biopsie liquide pour une détection plus large du cancer du sein. La plateforme de l'entreprise combine métabolomique et apprentissage automatique pour la détection précoce du cancer, en se concentrant sur le développement d'outils de diagnostic précis et accessibles.
BioMark Diagnostics (BMKDF) hat bedeutende Fortschritte in seinem Programm zur Erkennung von Brustkrebs angekündigt. Die Zusammenfassung des Unternehmens zur Entdeckung von Biomarkern für lobulären Brustkrebs (LBC) wurde beim 2024 San Antonio Breast Cancer Symposium akzeptiert. Die Forschung zeigt einen einfachen, leistungsstarken Metabolitentest zur Erkennung von LBC, der 10-15 % aller Brustkrebsfälle ausmacht. Dies folgt auf ihre Veröffentlichung im Oktober in der International Journal of Molecular Science, die einen neuartigen Flüssigbiopsietest zur breiteren Erkennung von Brustkrebs hervorhob. Die Plattform des Unternehmens kombiniert Metabolomik und maschinelles Lernen für die frühe Krebsdiagnose und konzentriert sich darauf, präzise und zugängliche Diagnosewerkzeuge zu entwickeln.
- Development of a novel metabolite-based blood test for Lobular Breast Cancer detection
- Research acceptance at prestigious San Antonio Breast Cancer Symposium 2024
- Recent publication in International Journal of Molecular Science validating breast cancer screening technology
- Integration of AI and ML tools to enhance diagnostic capabilities
- None.
BioMark Strengthens Liquid Biopsy Platform for Breast Cancer Detection
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced significant progress in its breast cancer program. The Company's liquid biopsy platform, leveraging metabolomics and machine learning, is demonstrating strong potential for early detection of breast cancer, especially for lobular breast cancer (LBC).
Poster presentation on Lobular Breast Cancer Research:
BioMark's abstract entitled "Targeted Human Plasma Metabolomics for Lobular Breast Cancer Biomarker Discovery" has been accepted at the 2024 San Antonio Breast Cancer Symposium (SABSC), from December 10-13, 2024, San Antonio, Texas. BioMark' Chief Scientific Officer, Jean-François Haince, will be presenting the results from a retrospective study on early lobular breast cancer metabolomics panel during the Spotlight Poster Session 1 on Wednesday, December 11, 2024, Time: 12:30 PM - 2:00 PM at the Henry B. Gonzalez Convention Center, San Antonio, Texas. The poster will be available on our website following the conclusion of the meeting. During the symposium, BioMark's team will engage with collaborating partners and analysts, fostering meaningful connections and advancing our shared mission to revolutionize cancer diagnosis. Interested parties may also request, in advance, a meeting with senior management at info@biomarkdiagnostics.com.
"We are thrilled to be invited once again to showcase our cutting-edge data on lobular breast cancer at the prestigious SABSC 2024, the world's largest international gathering of breast cancer experts. This esteemed event fosters intimate discussions among key opinion leaders, clinicians, and analysts, providing unparalleled insights into transformative clinical research. Our pioneering study demonstrates the versatility and efficacy of BioMark's AI-driven metabolomics platform in early cancer diagnosis. Notably, our research reveals a simple, high-performing metabolite-based test for detecting lobular breast cancer, paving the way for a potentially routine, cost-effective, and reliable blood-based screening for women at highest risk," says Rashid Bux, CEO and President of BioMark. He added, 'We're proud to share our innovative research with the global breast cancer community, further solidifying BioMark's position at the forefront of cancer diagnostics."
Building on Previous Breakthroughs:
This announcement follows publication in October of a paper titled "Identification of a Novel Biomarker Panel for Breast Cancer Screening" in the International Journal of Molecular Science (IJMS). This paper highlighted the company's innovative liquid biopsy assay for broader breast cancer detection.
Mr. Bux further adds, "The company remains committed to developing accurate and accessible tools for early cancer diagnosis. The company's liquid biopsy platform holds the potential to revolutionize breast cancer screening and improve patient outcomes. Furthermore, the company has been investing and integrating more AI and ML tools to extract valuable insights from data, empowering healthcare professionals to make informed decisions and improve patient care."
Breast cancer (BC) is the second leading cause of cancer death among women. Lobular breast cancer (LBC) is a subtype of breast cancer that is invasive and begins in the lobules, which are the milk-producing glands in the breast. It accounts for about 10
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved, or disapproved the content of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228880
FAQ
What is BioMark's (BMKDF) new breakthrough in breast cancer detection?
Where will BioMark (BMKDF) present its Lobular Breast Cancer research in December 2024?
What percentage of breast cancers does Lobular Breast Cancer represent according to BioMark's (BMKDF) research?
